Tessera Defense & Homeland Security (HLSQ) Stock Price, Financials & Analysis

Key Stats

Market Cap243,388.69

P/E0.00

P/S0.75

Div. Yield0.00

Total Debt (Qtr)2.39 Mn

Add ratio to table…

About

BiomX Inc. is a clinical stage product discovery company developing natural and engineered phage based therapies to target and kill specific harmful bacteria associated with chronic diseases such as diabetic foot infections. The company uses its proprietary research and development platform to screen identify and combine phage strains that can penetrate biofilms resist resistance and remain stable for manufacturing. Its product candidates are designed to treat conditions…

BiomX Inc. has not generated any revenue from product sales because all of its candidates remain in clinical development. The company funds its operations through government grants such as the $5.8 million received from the Medical Technology Enterprise Consortium and through private placements including the December 2025 sale of Series Y Convertible Preferred Stock and warrants for gross proceeds of $3.0 million. These financing activities support ongoing research and limited operational activities while the company evaluates strategic alternatives.

BiomX Inc. operates in the highly competitive biotechnology sector focused on phage therapy where it faces rivals such as Locus Biosciences Armata Pharmaceuticals and SNIPR Biome as well as academic programs and larger pharmaceutical companies with greater resources. Its competitive advantages stem from a proprietary phage discovery platform that integrates computational biology microbiology synthetic engineering and high throughput screening to produce optimized phage cocktails or personalized treatments. The company also benefits from collaborations with institutions such as the Walter Reed Army Institute of Research and the National Institutes of Health which provide access to phage libraries and clinical trial support.

The company serves patients suffering from bacterial infections linked to chronic diseases including individuals with diabetic foot infections diabetic foot osteomyelitis and potentially those with cystic fibrosis or atopic dermatitis. Its therapies are intended for use in hospital settings under the supervision of healthcare providers and are being evaluated in clinical trials that enroll adult patients with specific bacterial strains identified through diagnostic testing.

How Tessera Defense & Homeland Security ranks

Ranked against the 673 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/EImplausibly low multiple 0.00xMedian 17.3x Not meaningful —
P/FCFNegative free cash flow −0.01xMedian 17.9x 1^st
P/Operating cash flowNegative operating cash flow −0.01xMedian 16.4x 1^st
P/S 0.75xMedian 9.48x 92^nd
P/B 0.01xMedian 2.17x 99^th
P/Tangible book 0.01xMedian 2.41x 99^th
EV/EBITDA —Median 16.1x No data —
EV/EBITNegative EBIT −0.06xMedian 19.7x 3^rd
EV/Revenue —Median 6.87x No data —
EV/FCFNegative free cash flow −0.11xMedian 19.3x 4^th
EV/Operating cash flowNegative operating cash flow −0.11xMedian 16.2x 4^th
PEG (3Y EPS CAGR)Implausibly low multiple 0.00Median 0.35 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) —Median 10.1% No data —
Revenue CAGR (3Y) —Median 10.1% No data —
Gross profit growth (1Y) —Median 10.6% No data —
Gross profit CAGR (3Y) —Median 10.7% No data —
Operating income growth (1Y) 23.6%Median −0.5% 72^nd
Operating income CAGR (3Y) −10.6%Median 1.5% 34^th
Net income growth (1Y) −8.6%Median −6.1% 48^th
Net income CAGR (3Y) −2.2%Median −1.2% 48^th
EPS growth (1Y) 771%Median 20.8% 98^th
EPS CAGR (3Y) 237%Median 25.2% 99^th
Operating cash flow growth (1Y) 37.8%Median 0.0% 80^th
Operating cash flow CAGR (3Y) 5.9%Median 2.4% 55^th
Free cash flow growth (1Y) 37.9%Median 0.0% 79^th
Free cash flow CAGR (3Y) 5.9%Median 3.2% 54^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 73.3% No data —
EBITDA margin —Median −223% No data —
Operating margin —Median −238% No data —
Pretax margin —Median −229% No data —
Net margin —Median −233% No data —
FCF margin —Median −174% No data —
Operating cash flow margin —Median −170% No data —
Return on equity −543%Median −54.1% 4^th
Return on assets −289%Median −42.2% 6^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −596%Median −46.5% 3^rd
Asset turnover —Median 0.18x No data —
Cash conversion (OCF / net income)Net income is not positive 0.67xMedian 1.20x Not meaningful —
Stock comp / revenue —Median 27.7% No data —

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 8.5%Median 20.0% 69^th
Debt / equity 0.14xMedian 0.26x 64^th
Net debt / EBITDA —Median 1.82x No data —
Debt / FCFFree cash flow is not positive −0.13xMedian 3.03x Not meaningful —
Liabilities / assets 37.5%Median 32.8% 47^th
Equity / assets 62.5%Median 67.2% 47^th
Interest coverage −149xMedian −10.2x 18^th
Current ratio 0.24xMedian 4.47x 6^th
Quick ratio 0.09xMedian 3.69x 5^th
Cash ratio 0.06xMedian 3.33x 5^th
Altman Z-score —Median −0.74 No data —

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 2.3% No dividend —
Net buyback yieldAbove 100% of market value −1,059%Median −3.5% Not meaningful —
Shareholder yieldAbove 100% of market value −1,059%Median −2.4% Not meaningful —
Payout ratio (earnings) —Median 50.9% No dividend —
Payout ratio (FCF) —Median 45.2% No dividend —
Dividend growth (1Y) —Median 3.9% No dividend —
Dividend CAGR (3Y) —Median 3.5% No dividend —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,128.06 Bn	42.23	14.16	54.91 Bn
2	JNJ	Johnson & Johnson	615.47 Bn	29.26	6.28	49.04 Bn
3	ABBV	AbbVie Inc.	504.80 Bn	80.00	7.84	70.82 Bn
4	MRK	Merck & Co., Inc.	368.45 Bn	116.12	5.53	53.91 Bn
5	NVS	Novartis Ag	298.44 Bn	18.92	5.45	9.59 Bn
6	AZN	Astrazeneca Plc	261.92 Bn	25.07	4.46	32.35 Bn
7	AMGN	Amgen Inc	236.10 Bn	27.00	6.20	57.30 Bn
8	HLSQ	Tessera Defense & Homeland Security Inc.	0.00 Bn	0.00	0.75	0.00 Bn

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,128.06 Bn

42.23

14.16

54.91 Bn

JNJ

Johnson & Johnson

615.47 Bn

29.26

6.28

49.04 Bn

ABBV

AbbVie Inc.

504.80 Bn

80.00

7.84

70.82 Bn

MRK

Merck & Co., Inc.

368.45 Bn

116.12

5.53

53.91 Bn

NVS

Novartis Ag

298.44 Bn

18.92

5.45

9.59 Bn

AZN

Astrazeneca Plc

261.92 Bn

25.07

4.46

32.35 Bn

AMGN

Amgen Inc

236.10 Bn

27.00

6.20

57.30 Bn

HLSQ

Tessera Defense & Homeland Security Inc.

0.00 Bn

0.00

0.75

0.00 Bn

Tessera Defense & Homeland Security HLSQ

About

How Tessera Defense & Homeland Security ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Tessera Defense & Homeland Security HLSQ

About

How Tessera Defense & Homeland Security ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password